Positive initial data from a pivotal phase II expansion cohort evaluating investigational linvoseltamab (BCMAXCD3, formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory multiple myeloma, were presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
